Journal article
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
S Parakh, JJ Park, S Mendis, R Rai, W Xu, S Lo, M Drummond, C Rowe, A Wong, G McArthur, A Haydon, MC Andrews, J Cebon, A Guminski, RF Kefford, GV Long, AM Menzies, O Klein, MS Carlino
British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2017
DOI: 10.1038/bjc.2017.142
Abstract
Background:There is limited data on the efficacy of anti-programmed death 1 (PD-1) antibodies in patients (pts) with melanoma brain metastasis (BM), particularly those which are symptomatic.Method:We retrospectively assessed pts with melanoma BM treated with PD-1 antibodies, nivolumab and pembrolizumab. Clinicopathologic and treatment parameters were collected and outcomes determined for intracranial (IC) response rate (RR) using a modified RECIST criteria, with up to five IC target lesions used to determine IC response, disease control rate (DCR) and progression-free survival (PFS).Results:A total of 66 pts were identified with a median follow up of 7.0 months (range 0.8-24.5 months). A tot..
View full abstract